Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VESTIGE adjuvant nivolumab plus ipilimumab after resection for high-risk gastric or EGJ adenocarcinoma
2018-000406-36Phase 2Unknown
- Sponsor
- European Organisation for Research and Treatment of Cancer
- Start
- Oct 2018
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of nivolumab and ipilimumab in gastric adenocarcinoma, gastroesophageal junction adenocarcinoma and esophageal adenocarcinoma (EAC) (2 arms), sponsored by European Organisation for Research and Treatment of Cancer. Primary endpoint: Disease-free survival. Status: unknown.
02
Drugs
nivolumabipilimumab
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinomaesophageal adenocarcinoma (EAC)
Beyond the preview
Go deeper on 2018-000406-36.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-000406-36.